{"Jdmn7bIAAAAJ": [["Vishaal Rajani", 2020, "Tripartite signalling by NMDA receptors"], ["Ameet S Sengar", 2020, "Tripartite signalling by NMDA receptors"], ["Michael W Salter", 2020, "Tripartite signalling by NMDA receptors"], ["Mark Lowerison", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Marios-Nikos Psychogios", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Michael E Kelly", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Steven Peters", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Michael Hill", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Jeremy Rempel", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Derek Emery", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Sharon Kiszczak", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Daniel Roy", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Oh Young Bang", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Dominic Tse", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Martha Marko", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Bijoy K Menon", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Michael D Hill", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Joung-Ho Rha", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Brett Graham", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Leslie Zimmel", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ryan A McTaggart", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Kenneth Butcher", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ruchir A Shah", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Richard Owen", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Volker Puetz", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Jeremy L Rempel", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["George A Lopez", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Lori Campbell", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["YX Amy", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Karla J Ryckborst", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Muneer Eesa", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ashutosh Jadhav", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Stephen Van Gaal", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Francis Taylor", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Andrea Hanley", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ashfaq Shuaib", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Charlotte Zerna", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Prasanna Venkatesan", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Nancy Newcommon", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Glen Jickling", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Nishita Singh", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Donald F Frei", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Se\u00e1n Murphy", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Coleman O Martin", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Joseph Paul", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Stephen J Phillips", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Cameron G McDougall", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Joey English", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["John Wong", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Axel CR Rohr", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Peter Stys", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Erika Teleg", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Jason W Tarpley", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Linda Andersen", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Andrew Loockey", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Michael Tymianski", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Andrew Demchuk", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Johanna M Ospel", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Carol Kenney", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Alexandre Y Poppe", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Cari Jahraus", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Raul G Nogueira", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Eric Sauvageau", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Oiao Zhang", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Trevor Kotylak", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Richard H Swartz", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Jeanne Teitelbaum", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Richard Frayne", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Tom Yeo", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ren\u00e9 Chapot", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Shelagh Coutts", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["David Garman", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Robert Ashforth", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Mohammed A Almekhlafi", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Phillippe Couillard", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Hana Choe", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Timothy J Kleinig", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Bijoy Menon", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Amith Sitaram", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Supriya Save", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ondrej Volny", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ashley Ure", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Darcy Blackstock", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Tom Jeerakathil", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Brian A van Adel", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["William Morrish", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Karla Ryckborst", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Joseph L Schindler", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Nima Kashani", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Alim Mitha", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Samuel Wiebe", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Michelle Wright", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ji Hoe Heo", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Brian Buck", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["G\u00f6tz Thomalla", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ravinder Singh", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Cian O'Kelly", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Jennifer L Mandzia", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ronald F Budzik", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Darshan Doshi", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Staffan Holmin", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Craig Doram", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Johanna Ospel", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Mark W Lowerison", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Sidney Starkman", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["David Turkel-Parrella", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Paul A Burns", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Simerpreet Bal", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Gavin Hull", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Sanchea Wasyliw", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Shelly Bohn", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Piyush Ojha", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ankur Wadhwa", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Shawna M Cutting", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Mayank Goyal", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Thomas G Devlin", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ajit S Puri", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Bruce CV Campbell", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Rishi Gupta", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Nicole Blenkin", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Thalia S Field", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Brian H Buck", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Demetrios J Sahlas", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Kathy Heard", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Abdulaziz Alsultan", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Eric Smith", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Shuo Chen", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Diogo Haussen", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Shelagh B Coutts", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Manish Joshi", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Nicholas Maraj", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Aimen Moussaddy", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Frank L Silver", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ricardo A Hanel", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Aditya Bharatha", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Marie-Christine Camden", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Philip Barber", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Dar Dowlatshahi", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Saad Alqatani", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Debabrata Chakraborty", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Anitha Jambula", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Daniela Iancu", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Marina Saluzzi", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Mohammed Almekhlafi", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Andrew M Demchuk", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["John Thornton", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Simon Nagel", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Sung-Il Sohn", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Suresh Subramaniam", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Gary Klein", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Donald Heck", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Dominic Hul", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Ria Asuncion", 2020, "Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"], ["Jacqueline Ullman", 2020, "Gay, Bisexual, and Queer Men\u2019s Attitudes and Understandings of Intimate Partner Violence and Sexual Assault"], ["Kerry Robinson", 2020, "Gay, Bisexual, and Queer Men\u2019s Attitudes and Understandings of Intimate Partner Violence and Sexual Assault"], ["Nida Denson", 2020, "Gay, Bisexual, and Queer Men\u2019s Attitudes and Understandings of Intimate Partner Violence and Sexual Assault"], ["Georgia Ovenden", 2020, "Gay, Bisexual, and Queer Men\u2019s Attitudes and Understandings of Intimate Partner Violence and Sexual Assault"], ["Michael Salter", 2020, "Gay, Bisexual, and Queer Men\u2019s Attitudes and Understandings of Intimate Partner Violence and Sexual Assault"], ["Kate Huppatz", 2020, "Gay, Bisexual, and Queer Men\u2019s Attitudes and Understandings of Intimate Partner Violence and Sexual Assault"], ["Kai Noonan", 2020, "Gay, Bisexual, and Queer Men\u2019s Attitudes and Understandings of Intimate Partner Violence and Sexual Assault"], ["Peter Bansel", 2020, "Gay, Bisexual, and Queer Men\u2019s Attitudes and Understandings of Intimate Partner Violence and Sexual Assault"], ["Muhammad Faheem", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Kirill Zaslavsky", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Eric Deneault", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Balazs Varga", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Lia D\u2019Abate", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Stephen W Scherer", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Peter Pasceri", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Rebecca J Landa", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["James Ellis", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Alina Piekna", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Ryan KC Yuen", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Wen-Bo Zhang", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Rebecca SF Mok", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Andras Nagy", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Deivid C Rodrigues", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Wei Wei", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Marat Mufteev", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["P Joel Ross", 2020, "Synaptic dysfunction in human neurons with autism-associated deletions in PTCHD1-AS"], ["Katherine Halievski", 2020, "Sex-dependent mechanisms of chronic pain: A focus on microglia and P2X4R"], ["Shahrzad Ghazisaeidi", 2020, "Sex-dependent mechanisms of chronic pain: A focus on microglia and P2X4R"], ["Cathy Kezelman", 2020, "Understanding trauma as a system of psycho-social harm: contributions from the Australian Royal Commission into child sex abuse"], ["Kathleen McPhillips", 2020, "Understanding trauma as a system of psycho-social harm: contributions from the Australian Royal Commission into child sex abuse"], ["Elizabeth Roberts-Pedersen", 2020, "Understanding trauma as a system of psycho-social harm: contributions from the Australian Royal Commission into child sex abuse"], ["Michael Brudno", 2019, "Control of Long-Term Synaptic Potentiation and Learning by Alternative Splicing of the NMDA Receptor Subunit GluN1"], ["Ner Mu Saw", 2019, "Control of Long-Term Synaptic Potentiation and Learning by Alternative Splicing of the NMDA Receptor Subunit GluN1"], ["Celeste Leung", 2019, "Control of Long-Term Synaptic Potentiation and Learning by Alternative Splicing of the NMDA Receptor Subunit GluN1"], ["Hongbin Li", 2019, "Control of Long-Term Synaptic Potentiation and Learning by Alternative Splicing of the NMDA Receptor Subunit GluN1"], ["Arun K Ramani", 2019, "Control of Long-Term Synaptic Potentiation and Learning by Alternative Splicing of the NMDA Receptor Subunit GluN1"], ["Yongqian Wang", 2019, "Control of Long-Term Synaptic Potentiation and Learning by Alternative Splicing of the NMDA Receptor Subunit GluN1"], ["Zhengping Jia", 2019, "Control of Long-Term Synaptic Potentiation and Learning by Alternative Splicing of the NMDA Receptor Subunit GluN1"], ["Wenbo Zhang", 2019, "Control of Long-Term Synaptic Potentiation and Learning by Alternative Splicing of the NMDA Receptor Subunit GluN1"], ["YuShan Tu", 2019, "Control of Long-Term Synaptic Potentiation and Learning by Alternative Splicing of the NMDA Receptor Subunit GluN1"], ["Thimmasettappa Thippeswamy", 2019, "The impact of postsynaptic density 95 blocking peptide (Tat\u2010NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate \u2026"], ["Dean Hammond", 2019, "The impact of postsynaptic density 95 blocking peptide (Tat\u2010NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate \u2026"], ["Karen Tse", 2019, "The impact of postsynaptic density 95 blocking peptide (Tat\u2010NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate \u2026"], ["Edward Beamer", 2019, "The impact of postsynaptic density 95 blocking peptide (Tat\u2010NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate \u2026"], ["Deborah Simpson", 2019, "The impact of postsynaptic density 95 blocking peptide (Tat\u2010NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate \u2026"], ["Robert J Beynon", 2019, "The impact of postsynaptic density 95 blocking peptide (Tat\u2010NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate \u2026"], ["Graeme J Sills", 2019, "The impact of postsynaptic density 95 blocking peptide (Tat\u2010NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate \u2026"], ["Milind M Muley", 2019, "Chloride dysregulation through downregulation of KCC2 mediates neuropathic pain in both sexes"], ["Yves De Koninck", 2019, "Chloride dysregulation through downregulation of KCC2 mediates neuropathic pain in both sexes"], ["C\u00e9dric Gauthier", 2019, "Chloride dysregulation through downregulation of KCC2 mediates neuropathic pain in both sexes"], ["Steven A Prescott", 2019, "Chloride dysregulation through downregulation of KCC2 mediates neuropathic pain in both sexes"], ["Kwan Yeop Lee", 2019, "Chloride dysregulation through downregulation of KCC2 mediates neuropathic pain in both sexes"], ["Josiane CS Mapplebeck", 2019, "Chloride dysregulation through downregulation of KCC2 mediates neuropathic pain in both sexes"], ["Louis-Etienne Lorenzo", 2019, "Chloride dysregulation through downregulation of KCC2 mediates neuropathic pain in both sexes"], ["Melissa J Naschek", 2019, "Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease"], ["Robert E Featherstone", 2019, "Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease"], ["Karin E Borgmann-Winter", 2019, "Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease"], ["Chang-Gyu Hahn", 2019, "Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease"], ["Katelyn R Ward", 2019, "Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease"], ["Anamika Banerjee", 2019, "Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease"], ["Raymond L Gifford", 2019, "Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease"], ["Steven J Siegel", 2019, "Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease"], ["Olga Melnychenko", 2019, "Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease"], ["Janice Yi", 2019, "Src deficient mice demonstrate behavioral and electrophysiological alterations relevant to psychiatric and developmental disease"], ["Simon Beggs", 2019, "Priming of adult incision response by early-life injury: neonatal microglial inhibition has persistent but sexually dimorphic effects in adult rats"], ["Suellen M Walker", 2019, "Priming of adult incision response by early-life injury: neonatal microglial inhibition has persistent but sexually dimorphic effects in adult rats"], ["Orla Moriarty", 2019, "Priming of adult incision response by early-life injury: neonatal microglial inhibition has persistent but sexually dimorphic effects in adult rats"], ["Noam Peleg", 2019, "Submission to the Online Safety Charter consultation, April 2019"], ["Zhuozhi Wang", 2019, "SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons"], ["Melody Zhao", 2019, "SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons"], ["Tadeo Thompson", 2019, "SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons"], ["Shahryar Khattak", 2019, "SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons"], ["Fraser P McCready", 2019, "SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons"], ["Joelle El Hajjar", 2019, "SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons"], ["Asli Romm", 2019, "SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons"], ["Caitlin Loo", 2019, "SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons"], ["Parisa Shooshtari", 2019, "Characterization of Key Sexually Dimorphic Regulators in Pain Processing"], ["Sofia Assi", 2019, "Characterization of Key Sexually Dimorphic Regulators in Pain Processing"], ["Ameet Sengar", 2019, "Characterization of Key Sexually Dimorphic Regulators in Pain Processing"], ["Amy Tu", 2019, "Characterization of Key Sexually Dimorphic Regulators in Pain Processing"], ["David Finn", 2019, "Characterization of Key Sexually Dimorphic Regulators in Pain Processing"], ["Rosanna Weksberg", 2019, "Characterization of Key Sexually Dimorphic Regulators in Pain Processing"], ["Arun Ramani", 2019, "Characterization of Key Sexually Dimorphic Regulators in Pain Processing"], ["Milind Muley", 2019, "Characterization of Key Sexually Dimorphic Regulators in Pain Processing"], ["Vivian Wang", 2019, "Characterization of Key Sexually Dimorphic Regulators in Pain Processing"], ["David P Scanlon", 2019, "Strangers in strange lands: mitochondrial proteins found at extra-mitochondrial locations"], ["Stephen Farrall", 2019, "Acknowledgement of Reviewers for 2018"], ["Benjamin Goold", 2019, "Acknowledgement of Reviewers for 2018"], ["Don Weatherburn", 2019, "Acknowledgement of Reviewers for 2018"], ["Julie Stubbs", 2019, "Acknowledgement of Reviewers for 2018"], ["Emma Ryan", 2019, "Acknowledgement of Reviewers for 2018"], ["Julia Quilter", 2019, "Acknowledgement of Reviewers for 2018"], ["Christian Leuprecht", 2019, "Acknowledgement of Reviewers for 2018"], ["Mark Nolan", 2019, "Acknowledgement of Reviewers for 2018"], ["David Dixon", 2019, "Acknowledgement of Reviewers for 2018"], ["YongJei Lee", 2019, "Acknowledgement of Reviewers for 2018"], ["Tina Dolgopol", 2019, "Acknowledgement of Reviewers for 2018"], ["Randy Lippert", 2019, "Acknowledgement of Reviewers for 2018"], ["Rick Sarre", 2019, "Acknowledgement of Reviewers for 2018"], ["Avi Brisman", 2019, "Acknowledgement of Reviewers for 2018"], ["Mark Wood", 2019, "Acknowledgement of Reviewers for 2018"], ["Kristina Murphy", 2019, "Acknowledgement of Reviewers for 2018"], ["Darren Palmer", 2019, "Acknowledgement of Reviewers for 2018"], ["Tim Prenzler", 2019, "Acknowledgement of Reviewers for 2018"], ["Tony Jefferson", 2019, "Acknowledgement of Reviewers for 2018"], ["Sue Biddulph", 2019, "Acknowledgement of Reviewers for 2018"], ["Chris Greer", 2019, "Acknowledgement of Reviewers for 2018"], ["Roderic Broadhurst", 2019, "Acknowledgement of Reviewers for 2018"], ["Anthea McCarthy-Jones", 2019, "Acknowledgement of Reviewers for 2018"], ["Kelly Richards", 2019, "Acknowledgement of Reviewers for 2018"], ["Tanya Wyatt", 2019, "Acknowledgement of Reviewers for 2018"], ["Jesse Cale", 2019, "Acknowledgement of Reviewers for 2018"], ["Alexandra Cox", 2019, "Acknowledgement of Reviewers for 2018"], ["Mark Lauchs", 2019, "Acknowledgement of Reviewers for 2018"], ["Graham Farrell", 2019, "Acknowledgement of Reviewers for 2018"], ["Monica Serrano", 2019, "Acknowledgement of Reviewers for 2018"], ["Willem de Lint", 2019, "Acknowledgement of Reviewers for 2018"], ["Lorraine Mazerolle", 2019, "Acknowledgement of Reviewers for 2018"], ["Rebecca Wickes", 2019, "Acknowledgement of Reviewers for 2018"], ["Pamela Snow", 2019, "Acknowledgement of Reviewers for 2018"], ["Caroline Miles", 2019, "Acknowledgement of Reviewers for 2018"], ["Wim Bernasco", 2019, "Acknowledgement of Reviewers for 2018"], ["Eammon Carrabine", 2019, "Acknowledgement of Reviewers for 2018"], ["Barry Goldson", 2019, "Acknowledgement of Reviewers for 2018"], ["Ben Wadham", 2019, "Acknowledgement of Reviewers for 2018"], ["Jeffrey Ian Ross", 2019, "Acknowledgement of Reviewers for 2018"], ["Kathleen Daly", 2019, "Acknowledgement of Reviewers for 2018"], ["John Rynne", 2019, "Acknowledgement of Reviewers for 2018"], ["Daniel Trottier", 2019, "Acknowledgement of Reviewers for 2018"], ["Thalia Anthony", 2019, "Acknowledgement of Reviewers for 2018"], ["Luke McNamara", 2019, "Acknowledgement of Reviewers for 2018"], ["Melissa de Vel-Palumbo", 2019, "Acknowledgement of Reviewers for 2018"], ["Paul Mazerolle", 2019, "Acknowledgement of Reviewers for 2018"], ["Amanda Porter", 2019, "Acknowledgement of Reviewers for 2018"], ["Sue Trevaskes", 2019, "Acknowledgement of Reviewers for 2018"], ["Amanda Holt", 2019, "Acknowledgement of Reviewers for 2018"], ["David Bright", 2019, "Acknowledgement of Reviewers for 2018"], ["Ian Warren", 2019, "Acknowledgement of Reviewers for 2018"], ["Chad Whelan", 2019, "Acknowledgement of Reviewers for 2018"], ["Hilde Tubex", 2019, "Acknowledgement of Reviewers for 2018"], ["Marinella Marmo", 2019, "Acknowledgement of Reviewers for 2018"], ["Gregor Urbas", 2019, "Acknowledgement of Reviewers for 2018"], ["Ross McGarry", 2019, "Acknowledgement of Reviewers for 2018"], ["Alex Piquero", 2019, "Acknowledgement of Reviewers for 2018"], ["Anastasia Powell", 2019, "Acknowledgement of Reviewers for 2018"], ["Susan Dennison", 2019, "Acknowledgement of Reviewers for 2018"], ["Susanne Karstedt", 2019, "Acknowledgement of Reviewers for 2018"], ["Alyce McGovern", 2019, "Acknowledgement of Reviewers for 2018"], ["Anna Stewart", 2019, "Acknowledgement of Reviewers for 2018"], ["Asher Flynn", 2019, "Acknowledgement of Reviewers for 2018"], ["Jonathan Jackson", 2019, "Acknowledgement of Reviewers for 2018"], ["David Brown", 2019, "Acknowledgement of Reviewers for 2018"], ["Chris Trotter", 2019, "Acknowledgement of Reviewers for 2018"], ["Murray Lee", 2019, "Acknowledgement of Reviewers for 2018"], ["David Boarder-Giles", 2019, "Acknowledgement of Reviewers for 2018"]]}